Cargando…

EFFECTS OF β-HYDROXY-β-METHYLBUTYRATE SUPPLEMENTATION ON MUSCLE MASS AND STRENGTH IN ONABOTULINUMTOXIN TYPE-A-INJECTED AND CONTRALATERAL QUADRICEPS FEMORIS IN RABBITS

OBJECTIVE: To determine the effects of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB) on strength, muscle mass, and contractile material in muscle wasting induced by onabotulinumtoxin type-A (BoNT-A) injection into the quadriceps femoris muscles of New Zealand white rabbits. METHODS: A tota...

Descripción completa

Detalles Bibliográficos
Autores principales: FORTUNA, Rafael, SAWATSKY, Andrew, FULLER, John C., HERZOG, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Foundation for Rehabilitation Information 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638725/
https://www.ncbi.nlm.nih.gov/pubmed/34430979
http://dx.doi.org/10.2340/16501977-2866
Descripción
Sumario:OBJECTIVE: To determine the effects of the leucine metabolite β-hydroxy-β-methylbutyrate (HMB) on strength, muscle mass, and contractile material in muscle wasting induced by onabotulinumtoxin type-A (BoNT-A) injection into the quadriceps femoris muscles of New Zealand white rabbits. METHODS: A total of 21, female rabbits were divided into 3 groups (n = 7, each). Group 1 (Control) received intramuscular injection of saline. Groups 2 and 3 received intramuscular injection of BoNT-A (3.5 units/kg), with group 3 receiving supplementation with HMB (120 mg/kg-BW/day). Muscle morphology, mass, and strength were assessed 8 weeks later in both injected and non-injected contralateral limbs. RESULTS: Injected muscle strength of group 2 (BoNT-A) and group 3 (BoNT-A+HMB) was reduced by 63% and 60%, respectively, compared with Controls (p < 0.0001). Strength in contralateral muscles of group 2 was reduced by 23% vs Controls (p <0.002), while in group 3, strength was similar to Controls. Muscle mass in the injected muscles of the BoNT-A and BoNT-A+HMB groups was significantly reduced, by 46% and 48%, respectively. CONCLUSION: While HMB did not prevent loss of muscle strength and mass in the BoNT-A-injected musculature, it prevented significant loss of contractile material in the injected musculature and strength loss in the contralateral non-injected musculature.